Figures S1-12, Table 1 from BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Figures S1-12, Table 1. Figure S1: Macrophages confer melanoma cell resistance to PLX4720 and Dabrafenib. Figure S2: Macrophages activate MAPK signaling, but do not activate CRAF, ARAF, NF- κB, PDGFRβ and STAT3 signaling in melanoma cells. Figure S3: Effects of growth factors on melanoma cell growth in the presence of PLX4720. Figure S4: Effects of VEGF on BRAFi-induced growth inhibition and cell death. Figure S5: The effect of macrophages on expression of VEGF receptors in melanoma cells. Figure S6. Blockade of VEGF signaling with a VEGFR inhibitor, brivanib alaninate reverses macrophagemediated resistance to PLX4720. Figure S7: Blockade of VEGF signaling with an anti-VEGF antibody reverses macrophagemediated resistance to PLX4720. Figure S8: BRAF inhibition elicits potent effects in macrophages. Figure S9: Effects of combination therapy of PLX4720 and GW2580 on melanoma growth in a xenograft model. Figure S10: Targeting macrophages with a M-CSFR inhibitor, GW2580, has a modest effect on melanoma cell growth and cell death. Figure S11: Effects of GW2580 and/or PLX4720 on tumor angiogenesis and macrophage infiltration. Figure S12: Positive control for Ki67 and CD163 staining. Table 1. Summary of melanoma patient clinical information